English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Chlamydia trachomatis andNeisseria gonorrhoeae are common causes of sexually transmitted infections, and there is interest in screening SurePath liquid-based Pap (L-Pap) samples with Aptima Combo 2 (AC2), Amplicor (AMP), and ProbeTec ET (PT) assays. SurePath L-Pap samples and a cervical swab (CS) were collected from 394 women attending health clinics in Hamilton and Toronto, ON, Canada. L-Pap samples were tested with the three assays prior to being processed for cytology, and the CS sample was tested with AC2. The prevalence ofC. trachomatis was 8.9%, and that ofN. gonorrhoeae was 1.5%. By using the positives from CS testing, as well as CS negatives corresponding to L-Pap samples that tested positive in 2 of 3 assays, the sensitivities of AC2, AMP, and PT forC. trachomatis in precytology samples were calculated to be 97.1% (34 of 35 positive samples were detected), 91.4% (32 of 35 were detected), and 77.1% (27 of 35 were detected), respectively. Six women were infected withN. gonorrhoeae . After cytology processing, the results of testing the remaining liquid in the L-Pap vial and the cell-enriched fraction forC. trachomatis by AC2 showed positive agreements of 98.9% (kappa [k ], 0.93) and 98.7% (k , 0.92), respectively, with the results of testing precytology L-Pap samples. Although all testing showed high specificity, testing forC. trachomatis by AC2 was significantly more sensitive than testing by PT for SurePath samples (P = 0.02). Newer versions of AMP (Cobas 4800) and PT (Qx with XTR technology) need published evaluations for detectingC. trachomatis andN. gonorrhoeae in L-Pap samples.C. trachomatis testing can be performed with similar results on pre- and postcytology SurePath samples.

journal of clinical microbiology

Comparison of Three Assays for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in SurePath Pap Samples and the Role of Pre- and Postcytology Testing